Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon launches anti-CD-6 psoriasis biologic in India

This article was originally published in Scrip

Executive Summary

India's largest biotechnology firm, Biocon, has launched its first-in-class anti-CD6 monoclonal antibody, itolizumab (marketed as Alzumab), for chronic plaque psoriasis, on the domestic market.

Advertisement

Related Content

Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022413

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel